Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com

Royalty Pharma (NASDAQ:RPRX) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Separately, Citigroup restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $42.50.

Royalty Pharma Trading Down 1.6%

RPRX opened at $32.82 on Monday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company’s 50 day simple moving average is $32.37 and its two-hundred day simple moving average is $29.86. Royalty Pharma has a 1-year low of $24.05 and a 1-year high of $34.20. The firm has a market capitalization of $18.92 billion, a price-to-earnings ratio of 22.63, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.07. The firm had revenue of $839.00 million during the quarter, compared to analysts’ expectations of $724.69 million. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Analysts expect that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Royalty Pharma

Several hedge funds have recently added to or reduced their stakes in RPRX. Applied Finance Capital Management LLC lifted its position in Royalty Pharma by 3.0% in the 1st quarter. Applied Finance Capital Management LLC now owns 11,265 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 329 shares in the last quarter. Nissay Asset Management Corp Japan ADV raised its stake in shares of Royalty Pharma by 0.7% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company’s stock valued at $1,238,000 after buying an additional 349 shares during the last quarter. Keene & Associates Inc. lifted its holdings in Royalty Pharma by 1.9% in the 4th quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock valued at $495,000 after purchasing an additional 370 shares in the last quarter. National Bank of Canada FI boosted its stake in shares of Royalty Pharma by 21.8% in the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 371 shares during the period. Finally, Blue Trust Inc. grew its position in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.